Nuo Therapeutics, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Nuo Therapeutics, Inc. (AURX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $10.48 thousand as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-30
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $10.48K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $8.86K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $12.64K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $20.93K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $10.48K 10-K · filed 2026-03-30 |
| 2024-12-31 | $8.86K 10-K · filed 2026-03-30 |
| 2023-12-31 | $12.64K 10-K · filed 2025-04-01 |
| 2022-12-31 | $20.93K 10-K · filed 2024-04-19 |
| 2021-12-31 | $86.51K 10-K · filed 2023-04-17 |
| 2020-12-31 | $82.91K 10-K · filed 2022-04-15 |
| 2019-12-31 | $37.90K 10-K · filed 2022-04-15 |